At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 801 enrolled
Drug / intervention
Ticagrelor +2 moredrug
Likely dose
Ticagrelor 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned
In Brief
A Phase 3 clinical trial evaluating Ticagrelor, Clopidogrel, and 1 other intervention for Acute Coronary Syndrome and Percutaneous Coronary Intervention. Completed, enrolled 801 participants across 87 sites in 3 countries.
Detailed Summary
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (PCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionJul 2012
TodayJul 2026
First PostedFeb 11, 2011
Enrollment StartFeb 1, 2011
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.4 years ago
Interventions
Ticagrelordrug
90 mg, oral dose twice daily
Clopidogreldrug
75 mg, oral dose once daily
Acetylsalicylic acid ASAdrug
Low Dose ASA